


Please amend the application as follows:

In the claims:

Please cancel claims 8 and 9 without prejudice or disclaimer.

Please amend claims 1-7 as follows:

1. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

R¹ is hydrogen, methyl; or ethyl;

R² is methyl; or ethyl; or

R¹-N-R² together are a pyrrolidine ring;

A is a valyl, isoleucyl, allo-isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;

B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-leucyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, homoprolyl, hydroxyprolyl, or thiazolidine-4-carbonyl residue;






E is a prolyl, homoprolyl, hydroxyprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

X is ethyl, propyl, butyl, isopropyl, sec. butyl, tert.-butyl, cyclopropyl, or cyclopentyl;

G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, D-norvalyl, 1-aminopentyl-1-carbonyl, or 2,2-dimethylglycyl residue;


s is 0 or 1;

K is -NH-C₁₋₈-alkyl, -NH-C₃₋₈-alkenyl, -NH-C₃₋₈-alkinyl, -NH-C₆₋₈-cycloalkyl, -NH-C₁₋₄-alkene-C₃₋₈-cycloalkyl, C₁₋₄-alkyl-N-C₁₋₆-alkyl, in which ~~residues~~ one CH₂ group may be replaced by O or S, one H by phenyl or cyano, or 1, 2 or 3 H by F, except the N-methoxy-N-methylamino, N-benzylamino, or N-methyl-N-benzylamino residue, or K is



and the salts thereof with physiologically tolerated acids.

2. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

R^1 is hydrogen, methyl; or ethyl;

R^2 is methyl; or ethyl ; or

$\text{R}^1\text{-N-R}^2$ together are a pyrrolidine ring;

A is a valyl, isoleucyl, allo-isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;

B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-leucyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, homoprolyl, hydroxyprolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, homoprolyl, hydroxyprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

X is ethyl, propyl, butyl, isopropyl, sec. butyl, tert. butyl, cyclopropyl, or cyclopentyl;


G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, D-norvalyl, 1-aminopentyl-1-carbonyl, or 2,2-dimethylglycyl residue;


s is 0 or 1;

K -NHCH₃, -NHCH₂CH₃, -NH(CH₂)₂CH₃, -NH(CH₂)₃CH₃,
-NH(CH₂)₄CH₃, -NH(CH₂)₅CH₃, -NH(CH₂)₆CH₃,
-NHCH(CH₂)₇CH₃, -NHCH(CH₃)₂, -NHCH(CH₃)CH₂CH₃,
-NHCH(CH₂CH₃)₂, -NHCH(CH₂CH₂CH₃)₂, -NHC(CH₃)₃,

-NHCH(CH₂CH₃)CH₂CH₂CH₃, -NHCH(CH₃)CH(CH₃)₂,
-NHCH(CH₂CH₃)CH(CH₃)₂, -NHCH(CH₃)C(CH₃)₃,
-NH-cyclohexyl, -NH-cycloheptyl, -NH-cyclooctyl,
-N(CH₃)OCH₂CH₃, -N(CH₃)OCH₂CH₂CH₃, -N(CH₃)OCH(CH₃)₂,
-N(CH₃)O(CH₂)₃CH₃, -N(CH₃)OCH₂C₆H₅, -NH(CH₂)₂C₆H₅,
-NH(CH₂)₃C₆H₅, -NHCH(CH₃)C₆H₅, -NHC(CH₃)₂C₆H₅,
-NHC(CH₃)₂CH₂CH₃, -NHC(CH₃)(CH₂CH₃)₂, -NHCH[CH(CH₃)₂]₂, -
NHC(CH₃)₂CN, -NHCH(CH₃)CH(OH)C₆H₅, -NHCH₂-cyclohexyl,
-NHCH₂C(CH₃)₃, -NHCH₂CH(CH₃)₂, -NHCH₂CF₃, -NHCH(CH₂F)₂, -
NHCH₂CH₂F, -NHCH₂CH₂OCH₃, -NHCH₂CH₂SCH₃,
-NHCH₂CHCH₂, -NH-C(CH₃)₂CH=CH₂, -NHC(CH₃)₂C≡CH,
-NHC(CH₂CH₃)₂C≡CH, -NHC(CH₃)₂CH₂CH₂OH,
-NH(CH₂CH₂O)₂CH₂CH₃, -NHC(CH₃)₂CH(CH₃)₂,
-NHC(CH₃)₂CH₂CH₂CH₃, -NHC(CH₃)₂CH₂C₆H₅,
-N(OCH₃)CH(CH₃)₂, -N(OCH₃)CH₂CH₃, -N(OCH₃)CH₂CH₂CH₃,
-N(OCH₃)CH₂C₆H₅, -N(OCH₃)C₆H₅, -N(CH₃)OC₆H₅,
-NHCH[CH(CH₃)₂]₂, -N(OCH₃)CH₂CH₂CH₂CH₃,


or K is





and the salts thereof with physiologically tolerated acids.

3. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

R¹ is hydrogen, methyl; or ethyl;

R² is methyl; or ethyl ;

A is a valyl, isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;


B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;


E is a prolyl, homoprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

- X is ethyl, propyl, isopropyl, sec. butyl, tert.-butyl, or cyclopropyl;
G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, or 2,2-dimethylglycyl residue;
s is 0 or 1;
K is -NH-C₁₋₈-alkyl, -NH-C₆₋₈-cycloalkyl, -NH-CH₂-cyclohexyl, C₁₋₄-alkyl-N-C₁₋₆-alkyl, in which ~~residues~~ one CH₂ group may be replaced by O, one H by phenyl or 1 or 2 H by F, except the N-methoxy-N-methylamino, N-benzylamino or N-methyl-N-benzylamino residue, or K is

C1



4. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

R^1 is methyl;

R^2 is methyl;

A is a valyl, isoleucyl, 2-tert-butylglycyl, or 2-ethylglycyl;

B is a N-methyl-valyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;


X is ethyl, isopropyl, sec. butyl, or tert. butyl ;


G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, or 2,2-dimethylglycyl residue;

s is 0 or 1;


K is -NH-C₁₋₈-alkyl, -NH-C₆₋₈-cycloalkyl, -NH-CH₂-cyclohexyl, C₁₋₄-alkyl-N-C₁₋₆-alkyl, in which ~~residues~~ one CH₂ group may be replaced by O, one H by phenyl or 1 or 2 H by F, except the N-methoxy-N-methylamino, N-benzylamino or N-methyl-N-benzylamino-residue, or K

is





5. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

R^1 is methyl;

R^2 is methyl;

A is a valyl, isoleucyl, or 2-tert-butylglycyl residue;

B is a N-methyl-valyl, N-methyl-isoleucyl, or N-methyl-2-tert-butylglycyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, cis-4-fluoro-L-prolyl or cis-4-chloro-L-prolyl residue;


X is isopropyl, sec. butyl, or tert.-butyl ;

s is 0 or 1;

K is $\text{-NHC(CH}_3)_3$, $\text{-NHCH(CH}_2\text{CH}_2\text{)CH(CH}_3)_2$, $\text{-NHCH(CH}_3\text{)C(CH}_3)_3$, $\text{-N(CH}_3\text{)OCH}_2\text{CH}_3$, $\text{-N(CH}_3\text{)OCH}_2\text{CH}_2\text{CH}_3$, $\text{-N(CH}_3\text{)OCH(CH}_3)_2$, $\text{-N(CH}_3\text{)O(CH}_2)_3\text{CH}_3$, $\text{-N(CH}_3\text{)OCH}_2\text{C}_6\text{H}_5$, $\text{-NHC(CH}_3)_2\text{C}_6\text{H}_5$, $\text{-NHC(CH}_3)_2\text{CH}_2\text{CH}_3$, $\text{-NHC(CH}_3\text{) (CH}_2\text{CH}_3)_2$,


-NHCH[CH(CH₃)₂]₂, -NHC(CH₃)₂CN, -NHCH(CH₃)CH(OH)C₆H₅,
-NH-C(CH₃)₂CH=CH₂, -NHC(CH₃)₂C≡CH,
-NHC(CH₂CH₃)₂C≡CH, -NHC(CH₃)₂CH₂CH₂OH,
-NHC(CH₃)₂CH(CH₃)₂, -NHC(CH₃)₂CH₂CH₂CH₃,
-NHC(CH₃)₂CH₂C₆H₅, -N(OCH₃)CH(CH₃)₂, -N(OCH₃)CH₂CH₃,
-N(OCH₃)CH₂CH₂CH₃, -N(OCH₃)CH₂C₆H₅, -N(OCH₃)C₆H₅,
-N(CH₃)OC₆H₅, -N(OCH₃)CH₂CH₂CH₂CH₃,

or K is



and the salts thereof with physiologically tolerated acids.

6. (Currently Amended) ~~Novel~~ Peptides of the formula I



I


where

R¹ is methyl;

R² is methyl;


A is a valyl residue;
B is a N-methyl-valyl residue;
D is a prolyl residue;
E is a prolyl residue;
X is isopropyl ;
s is 0 or 1;
K is -NHC(CH₃)₃, -NHCH(CH₂CH₂)CH(CH₃)₂, -NHCH(CH₃)C(CH₃)₃, -N(CH₃)OCH₂CH₃, -N(CH₃)OCH₂CH₂CH₃, -N(CH₃)OCH(CH₃)₂, -N(CH₃)O(CH₂)₃CH₃, -N(CH₃)OCH₂C₆H₅, -NHC(CH₃)₂C₆H₅, -NHC(CH₃)₂CH₂CH₃, -NHC(CH₃) (CH₂CH₃)₂, -NHCH[CH(CH₃)₂]₂, -NHC(CH₃)₂CN, -NHCH(CH₃)CH(OH)C₆H₅, -NH-C(CH₃)₂CH=CH₂, -NHC(CH₃)₂C≡CH, -NHC(CH₂CH₃)₂C≡CH, -NHC(CH₃)₂CH₂CH₂OH, -NHC(CH₃)₂CH(CH₃)₂, -NHC(CH₃)₂CH₂CH₂CH₃, -NHC(CH₃)₂CH₂C₆H₅, -N(OCH₃)CH(CH₃)₂, -N(OCH₃)CH₂CH₃, -N(OCH₃)CH₂CH₂CH₃, -N(OCH₃)CH₂C₆H₅, -N(OCH₃)C₆H₅, -N(CH₃)OC₆H₅, -N(OCH₃)CH₂CH₂CH₂CH₃,

or K is



and the salts thereof with physiologically tolerated acids.

7. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

R^1 is methyl;

R^2 is methyl;

A is a valyl, isoleucyl, or 2-tert-butylglycyl residue;

B is a N-methyl-valyl, N-methyl-isoleucyl, or N-methyl-2-tert-butylglycyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl residue;


X is isopropyl, sec. butyl, or tert.-butyl ;

G is a D-2-tert.butylglycyl, D-isoleucyl, 2,2-dimethylglycyl residue, D-valyl or L-2-tert.butylglycyl;


s is 1;

K is $-NHCH_3$, $-NHCH_2CH_3$, $-NH(CH_2)_2CH_3$, $-NH(CH_2)_3CH_3$, $-NH(CH_2)_4CH_3$, $-NH(CH_2)_5CH_3$, $-NHCH(CH_3)_2$, $-NHCH(CH_3)CH_2CH_3$, $-NHCH(CH_2CH_3)_2$, $-NHC(CH_3)_3$, $-NH$ -cyclohexyl, $-NHC(CH_3)_2CN$, $-NCH(CH_3)_2C\equiv CH$ or $-NHC(CH_3)_2CONH_2$;

or K is



or



and the salts thereof with physiologically tolerated acids.

8. (Cancelled)

9. (Cancelled)

10. (Previously Added) The peptide of claim 1, wherein the formula I is



cl